Squamous Cell Carcinoma | Norton Healthcare

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Indication: Squamous Cell Carcinoma

Phase III Study of Buparlisib (AN2025) Plus Paclitaxel Compared to Paclitaxel Alone in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Sub-indication: Head and Neck Cancer

Study Type: Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Adlai Nortye USA Inc

Learn more at ClinicalTrials.gov

Email for more information: Head&Neck-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Squamous Cell Carcinoma Clinical Trial

Schedule an Appointment